Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400:1345–62. https://doi.org/10.1016/S0140-6736(22)01200-4.

Article  CAS  PubMed  Google Scholar 

Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681–93. https://doi.org/10.1016/j.jhep.2021.11.018.

Article  PubMed  Google Scholar 

Cheung TK, Lai CL, Wong BCY, Fung J, Yuen MF. Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. Aliment Pharmacol Ther. 2006;24:573–83. https://doi.org/10.1111/j.1365-2036.2006.03029.x.

Article  PubMed  Google Scholar 

Bruix J, Cheng A-L, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol. 2017;67:999–1008. https://doi.org/10.1016/j.jhep.2017.06.026.

Article  CAS  PubMed  Google Scholar 

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. New Engl J Med. 2020;382:1894–905. https://doi.org/10.1056/NEJMoa1915745.

Article  CAS  PubMed  Google Scholar 

Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022. https://doi.org/10.1056/EVIDoa2100070.

Article  PubMed  Google Scholar 

Ducreux M, Abou-Alfa GK, Bekaii-Saab T, Berlin J, Cervantes A, de Baere T, et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022. ESMO Open. 2023;8. https://doi.org/10.1016/j.esmoop.2023.101567.

Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016;65:938–43. https://doi.org/10.1016/j.jhep.2016.05.044.

Article  PubMed  Google Scholar 

Zhang X-P, Gao Y-Z, Chen Z-H, Chen M-S, Li L-Q, Wen T-F, et al. An eastern hepatobiliary surgery hospital/portal vein tumor thrombus scoring system as an aid to decision making on hepatectomy for hepatocellular carcinoma patients with portal vein tumor thrombus: a multicenter study. Hepatology. 2019;69:2076–90. https://doi.org/10.1002/hep.30490.

Article  PubMed  Google Scholar 

Pawlik TM, Poon RT, Abdalla EK, Ikai I, Nagorney DM, Belghiti J, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery. 2005;137:403–10. https://doi.org/10.1016/j.surg.2004.12.012.

Article  PubMed  Google Scholar 

Lu J, Zhang X-P, Zhong B-Y, Lau WY, Madoff DC, Davidson JC, et al. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. Lancet Gastroenterol Hepatol. 2019;4:721–30. https://doi.org/10.1016/S2468-1253(19)30178-5.

Article  PubMed  Google Scholar 

Costentin CE, Decaens T, Laurent A, Nault J-C, Paule B, et al. Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: a propensity score analysis. Liver Int. 2017;37:1869–76. https://doi.org/10.1111/liv.13491.

Article  CAS  PubMed  Google Scholar 

Yoon SM, Ryoo B-Y, Lee SJ, Kim JH, Shin JH, An JH, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. JAMA Oncol. 2018;4:661–9. https://doi.org/10.1001/jamaoncol.2017.5847.

Article  PubMed  PubMed Central  Google Scholar 

Dawson LA, Winter KA, Knox JJ, Zhu AX, Krishnan S, Guha C, et al. NRG/RTOG 1112: randomized phase III study of sorafenib vs stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC). J Clin Oncol. 2023. https://doi.org/10.1200/JCO.2023.41.4_suppl.489.

Article  Google Scholar 

Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2007;37:676–91. https://doi.org/10.1111/j.1872-034X.2007.00119.x.

Article  PubMed  Google Scholar 

Dawson LA, Eccles C, Craig T. Individualized image guided iso-NTCP based liver cancer SBRT. Acta Oncol. 2006;45(7):856–64. https://doi.org/10.1080/02841860600936369.

Article  PubMed  Google Scholar 

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90. https://doi.org/10.1056/NEJMoa0708857.

Article  CAS  PubMed  Google Scholar 

Study Details. Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/study/NCT01730937.

Study Details. Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP). ClinicalTrials.gov. Available at: https://clinicaltrials.gov/study/NCT00892658?cond=Sorafenib-RT%20in%20Treating%20Hepatocellular%20Carcinoma%20(SHEP)&rank=1

Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399–424. https://doi.org/10.1080/00273171.2011.568786.

Article  PubMed  PubMed Central  Google Scholar 

Patel R, Aslam A, Parikh ND, Mervak B, Mubarak E, Higgins L, et al. Updates on LI-RADS treatment response criteria for hepatocellular carcinoma: focusing on MRI. J Magn Reson Imag. 2023;57:1641–54. https://doi.org/10.1002/jmri.28659.

Article  Google Scholar 

Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13. https://doi.org/10.1097/01.sla.0000133083.54934.ae.

Article  PubMed  PubMed Central  Google Scholar 

Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011;149:713–24. https://doi.org/10.1016/j.surg.2010.10.001.

Article  PubMed  Google Scholar 

Finn RS, Galle PR, Ducreux M, Cheng A-L, Reilly N, Nicholas A, et al. Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and/or contralateral portal vein invasion in imbrave150. Liver Cancer. 2024. https://doi.org/10.1159/000539897.

Article  PubMed  PubMed Central  Google Scholar 

Wang K, Guo WX, Chen MS, Mao YL, Sun BC, Shi J, et al. Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus: a large-scale, multicenter, propensity mathching score analysis. Medicine. 2016;95:e3015. https://doi.org/10.1097/MD.0000000000003015.

Article  PubMed  PubMed Central  Google Scholar 

Silva JP, Berger NG, Tsai S, Christians KK, Clarke CN, Mogal H, et al. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. HPB. 2017;19:659–66. https://doi.org/10.1016/j.hpb.2017.04.016.

Article  PubMed  Google Scholar 

Chow PKH, Gandhi M, Tan S-B, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in asia-pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36:1913–21. https://doi.org/10.1200/JCO.2017.76.0892.

Article  CAS  PubMed  Google Scholar 

Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux G-P, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1624–36. https://doi.org/10.1016/S1470-2045(17)30683-6.

Article  CAS  PubMed  Google Scholar 

Munoz-Schuffenegger P, Barry A, Atenafu EG, Kim J, Brierley J, Ringash J, et al. Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion. Radiother Oncol. 2021;156:120–6. https://doi.org/10.1016/j.radonc.2020.11.033.

Article  CAS  PubMed  Google Scholar 

Liu CL, Fan ST, Cheung ST, Lo CM, Ng IO, Wong J. Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma. Ann Surg. 2006;244:194–203. https://doi.org/10.1097/01.sla.0000225095.18754.45.

Article  PubMed  PubMed Central  Google Scholar 

Juloori A, Katipally RR, Lemons JM, Singh AK, Iyer R, Robbins JR, et al. Phase 1 randomized trial of stereotactic body radiation therapy followed by nivolumab plus ipilimumab or nivolumab alone in advanced/unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2023;115:202. https://doi.org/10.1016/j.ijrobp.2022.09.052.